GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Turk Ilac ve Serum Sanayi (IST:TRILC) » Definitions » EBIT

Turk Ilac ve Serumnayi (IST:TRILC) EBIT : ₺225 Mil (TTM As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Turk Ilac ve Serumnayi EBIT?

Turk Ilac ve Serumnayi's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was ₺85 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was ₺225 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Turk Ilac ve Serumnayi's annualized ROC % for the quarter that ended in Sep. 2023 was 11.02%. Turk Ilac ve Serumnayi's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 36.83%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Turk Ilac ve Serumnayi's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 4.38%.


Turk Ilac ve Serumnayi EBIT Historical Data

The historical data trend for Turk Ilac ve Serumnayi's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turk Ilac ve Serumnayi EBIT Chart

Turk Ilac ve Serumnayi Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial 41.60 54.20 82.13 78.94 164.26

Turk Ilac ve Serumnayi Quarterly Data
Dec17 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.55 32.83 34.91 72.15 85.22

Competitive Comparison of Turk Ilac ve Serumnayi's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Turk Ilac ve Serumnayi's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Turk Ilac ve Serumnayi's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Turk Ilac ve Serumnayi's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Turk Ilac ve Serumnayi's EV-to-EBIT falls into.



Turk Ilac ve Serumnayi EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turk Ilac ve Serumnayi  (IST:TRILC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Turk Ilac ve Serumnayi's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=124.396 * ( 1 - 1.52% )/( (983.376 + 1240.238)/ 2 )
=122.5051808/1111.807
=11.02 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1195.404 - 181.953 - ( 30.075 - max(0, 490.684 - 592.847+30.075))
=983.376

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1605.532 - 347.504 - ( 17.79 - max(0, 720.641 - 849.078+17.79))
=1240.238

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Turk Ilac ve Serumnayi's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=340.864/( ( (488.231 + max(342.546, 0)) + (605.833 + max(414.354, 0)) )/ 2 )
=340.864/( ( 830.777 + 1020.187 )/ 2 )
=340.864/925.482
=36.83 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(446.66 + 54.567 + 59.118) - (181.953 + 0 + 35.846)
=342.546

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(722.563 + 44.3 + 61.948) - (347.504 + 0 + 66.953)
=414.354

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Turk Ilac ve Serumnayi's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=225.102/5138.925
=4.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turk Ilac ve Serumnayi EBIT Related Terms

Thank you for viewing the detailed overview of Turk Ilac ve Serumnayi's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Turk Ilac ve Serumnayi (IST:TRILC) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Bügduz Mah. Enver Pasa Cad., No: 8 Akyurt, Ankara, TUR, TR 06750
Turk Ilac ve Serum Sanayi is engaged in the production of human pharmaceuticals and vaccines.

Turk Ilac ve Serumnayi (IST:TRILC) Headlines

No Headlines